Hims has risen by over 50% this week, investors are paying attention to the impact of the Trump administration's health secretary's policy on the company's transformation of its GLP-1 weight loss drug business.

Hims & Hers Health rose by about 10%, reaching $29.78, marking the fifth consecutive trading day of gains, with a total increase of over 51% so far this week. Earlier this week, U.S. Department of Health and Human Services Secretary Robert F. Kennedy announced that the Food and Drug Administration plans to convene a Drug Compounding Advisory Committee meeting to review whether peptides can be included in the "503A Bulk List." This designation allows drugs to be compounded based on individual prescriptions rather than mass production. For Hims, the more significant story is that as the company guides members towards using brand-name drugs rather than higher-profit GLP-1 compounds, expanding the compounding of peptides could open up new sources of revenue. This telemedicine company has been preparing for its peptide business for years. The FDA's review process has just begun, and the Drug Compounding Advisory Committee meeting is scheduled for July 2026.